Wells Fargo downgraded West Pharm (NYSE:WST) from Outperform to Market Perform in a report released today.
- Updated: September 20, 2016
Wells Fargo has downgraded West Pharm (NYSE:WST) from Outperform to Market Perform in a report released on 9/21/2016.
Just yesterday West Pharm (NYSE:WST) traded -6.49% lower at $81.32. West Pharm’s 50-day moving average is $81.54 and its 200-day moving average is $74.86. The last stock price is up 1.58% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 369,071 shares of WST traded hands, down from an average trading volume of 405,067
Recent Performance Chart
West Pharm has 52 week low of $52.79 and a 52 week high of $84.33 with a PE ratio of 55.38 and has a market capitalization of $0.
In addition to Wells Fargo reporting its stock price target, a total of 4 brokerages have issued a ratings update on the company. The average stock price target is $66.00 with 2 brokerages rating the stock a strong buy, 1 brokerage rating the stock a buy, 1 brokerage rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
Brief Synopsis On West Pharm (NYSE:WST)
West Pharmaceutical Services, Inc. (West) is a manufacturer of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. The Company's segments include Pharmaceutical Packaging Systems segment (Packaging Systems) and the Pharmaceutical Delivery Systems segment (Delivery Systems). Its Packaging Systems segment includes primary packaging components and systems for injectable drug delivery, other components used in syringe, intravenous and blood collection systems, and prefillable syringe components. Its Delivery Systems segment includes safety and administration systems, multi-component systems for drug containment and administration and various custom contract-manufacturing solutions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.